3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety

Details for Australian Patent Application No. 2004285913 (hide)

Owner Glaxo Group Limited

Inventors Handlon, Anthony L; Barvian, Kevin K; Hyman, Clifton E; Hertzog, Donald L

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004285913

PCT Pub. Number WO2005/042541

Priority 60/513,800 23.10.03 US

Filing date 21 October 2004

Wipo publication date 12 May 2005

International Classifications

C07D 495/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

Event Publications

11 May 2006 PCT application entered the National Phase

  PCT publication WO2005/042541 Priority application(s): WO2005/042541

23 July 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004285920-Substituted heterocyclic compounds and methods of use

2004285912-Process for preparing moisture-curable, polyether urethanes with reactive silane groups and their use as sealants, adhesives and coatings